An animal health company has applied to "increase the dose rate" of the controversial antibiotic florfenicol in Tasmanian salmon farms, the federal regulator has confirmed. Abbey Labs seeks to increase florfenicol use on Tasmanian salmon farms, raising concerns over ecological risks and regulatory scrutiny after permit revocation. Abbey Labs seeks approval for higher florfenicol doses in Tasmanian salmon farms as regulators assess environmental and residue risks.